A Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
Ensho Therapeutics, Inc.
Summary
The purpose of this study is to evaluate the pharmacokinetics, safety, and tolerability of NSHO-101 in Healthy Participants.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: * Participants (males and females) at least 18 years of age * Ability to provide written informed consent * In good heath as determined by medical evaluation, * Willing and able to comply with trial restrictions, procedures, and requirements Exclusion Criteria: * Known sensitivity to any components of the IMP * History of relevant drug hypersensitivity * Presents or has a history of clinically significant diseases * History of difficulty swallowing tablets or capsules. * Any physical examination findings or medical history that might place the participant at an unaccepta…
Interventions
- DrugNSHO-101
Dose form - tablet Route of administration - oral Regimen / Treatment period - QD for 14 days
Location
- Cenexel Anaheim CAAnaheim, California